Astrikon may consider withdrawing from the vaccine business

On August 23, according to foreign media reports, Astrakan CEO Su Boke said: "In the long run, the company may not continue to engage in vaccine business."

Suboko said that the company is currently committed to developing antibody therapy combinations for viruses such as new coronary virus and respiratory virus RSV. However, when talking about the new crown vaccine, he frankly said: "I can't be sure if we will be there." In addition, for whether Astraikon will also expand other infectious vaccine business, Suboko said that the company is in Related evaluation.

However, Suboko said that "the company does not regret developing a new crown vaccine with Oxford University" because this product has saved about 6 million people around the world.

At the end of April 2020, Astrakang announced the cooperation with the University of Oxford University in the United Kingdom to develop and produce the "AZD1222" new crown virus candidate vaccine. On December 30 of that year, when the product was approved to be listed in the UK, the British government announced that it had scheduled 100 million doses of the vaccine and planned to be vaccinated by 50 million people.

However, due to thrombosis and even deaths in the vaccinator, Astrakon's new crown vaccine was suspended by at least 15 European countries such as France and Germany in the first half of 2021. Nevertheless, the product still made Astraikon make a lot of money: According to the company's 2021 annual report, the annual sales of the new crown vaccine reached 4 billion U.S. dollars, second only to the star anti -cancer drug "Tyrisa".

On August 6, 2020, Kangtai Biological has announced that he has achieved cooperation with Astra Cand to develop, produce, supply and commercialize AZD1222 in China.

- END -